The niacin/laropiprant group, in comparison with the placebo group, was associated with a “highly significant excess of participants with fatal or nonfatal serious adverse events (7137 [55.6%] versus 6762 [52.7%]), with many participants having more than one serious adverse event,” the researchers reported [ 13 ].
← all excerpts
Beyond Statins: Emerging Evidence for HDL-Increasing Therapies and Diet in Treating Cardiovascular Disease.
1
—
—